GSK’s Q3 results buoyed by long-acting HIV jab
Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts, with five new long-acting product launches now expected by 2030….
ViiV
Viiv/GSK pledge $8 mln ahead of Global Fund summit
GSK and HIV specialist ViiV Healthcare have pledged $8 million to the Global Fund, representing the biggest commitment to date from a private sector company…